alexa Hazardous Effect Free From Decontamination | OMICS International
ISSN: 2150-3494
Chemical Sciences Journal
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hazardous Effect Free From Decontamination

Hideharu Shintani*

Faculty of Science and Engineering, Chuo University, 1-13-27, Kasuga, Bunkyo, 112-8551, Tokyo, Japan

*Corresponding Author:
Hideharu Shintani
Faculty of Science and Engineering
Chuo University, 1-13-27, Kasuga
Bunkyo, 112-8551, Tokyo, Japan
TEL: +81425922336
FAX: +81425922336
E-mail: [email protected]

Received date: June 01, 2014; Accepted date: June 03, 2014; Published date: June 10, 2014

Citation: Hideharu Shintani (2014) Hazardous Effect Free From Decontamination. Chem Sci j 5:e103. doi: 10.4172/2150-3494.10000e103

Copyright: © Fatme Al Anouti, 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Chemical Sciences Journal

Editorial

Adventitious agents are those that are not inherent in the production of biopharmaceuticals. Microsbial adventitious agents, Microbiocidal agents, help for inactivation of viruses, bacteria, fungi, mycoplasma, bacterial spore and sometimes prion. Bovine spongiform encephalopathy (BSE) agents, abnormal prions, are also potential adventitious agents. Adventitious agents can be introduced during establishment of cell lines, cell culture/fermentation, capture and downstream processing steps, formulation/filling, and even during drug delivery Therapeutic biotechnology products must have excellent safety characteristics. However, the potential introduction of adventitious agents must continually be evaluated for safety. The testing procedures that is performed for this purpose is addressed in regulatory documents that include ICH guidelines, European U.S., and Japanese Pharmacopoeia (EP,USP and JP) documents. In some cases, 9 CFR (U.S. Code of Federal Regulations) and 21 CFR, 211 and 610 are also applicable.

Since biopharmaceuticals encompass many types of products, there is considerable variability in risks from adventitious agents. In all cases, however, the use of Good Manufacturing Practices (GMPs) (e.g.environmental controls, control of raw materials and personnel flow, and cleaning), suitable safety testing programs, and process validation (including evaluation for bacterial spore and sometimes prion inactivation) helps to ensure patient confidence in biopharmaceuticals. As shown in the Table 1, prion is thought to be the most tolerable protein followed to bacterial spores. Therefore, prion and bacterial spore inactivation is the most important concern for avoiding deterioration. Some products have minimal inherent risk associated with the introduction of adventitious agents (e.g.recombinant products produced in bacteria). Other types of products, such as those used for cell or gene therapy, are often at the other end of the spectrum and may be associated with greater risk due to their inability to tolerate rigorous processing conditions. Greater potential risks are often associated with the use of human cells and anima1-derived raw materials. Of particular concern are materials derived from bovine and porcine sources. When viable cells are a component of the product (as in ex vivo transduction), there may not be sufficient time to perform the required safety testing. In such cases, product may be released prior to completion of relevant tests for adventitious agents, although this testing is still mandated in order to demonstrate that the processes are being performed under adequate controls to maintain patient safety. A risk/benefit analysis determines whether the use of these products is warranted. We need to prevent and control of risks arising from various stages of production. We must confirm that several risks are associated with various sources and must not overlook the risks associated with several sources.

chemical-sciences-journal-tolerance-among-microorganisms-against

Table 1: 1: General tolerance among microorganisms against inactivation agents. Prion is thought to be the greatest and next is spore. This order is unchanged. Citation is from McDonnell G.E. In Antisepsis, Disinfection, and Sterilization, ASM Press, Washington, 2007.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12035
  • [From(publication date):
    June-2014 - Feb 24, 2018]
  • Breakdown by view type
  • HTML page views : 8197
  • PDF downloads : 3838
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version